Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Romero, J. I. Larco, I. Bobolea, C. Villasante, P. Barranco, S. Quirce, R. Alvarez-Sala (Madrid, Spain). Follow-up of patients with moderate-severe allergic asthma treated with omalizumab. Eur Respir J 2010; 36: Suppl. 54, 3961

Member's Comments

No comment yet.

Related content which might interest you: Treatment and outcomes in patients with asthma and allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 576s Year: 2005 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Safety of omalizumab therapy in children with allergic asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 The evaluations of allergic rhinitis symptoms in patients with asthma and allergic rhinitis with the addiing of montelukast in asthma treatment Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Allergic rhinitis neither routinely diagnosed nor treated in asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 249s Year: 2005 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Omalizumab in severe adult atopic dermatitis associated to mild asthma treated with omalizumab Source: Annual Congress 2012 - Asthma: assessment and treatment Year: 2012 The effectiveness of omalizumab in steroid-dependent asthma patients Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009